Skip to main content

Clinical trial ERA-223

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Organ prostate
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Bayer
EudraCT Identifier 2013-003438-33
Inclusion criteria *Histologically confirmed adenocarcinoma of the prostate*Prostate cancer progression documented by PSA according to the Prostate CancerWorking Group 2 (PCWG2) criteria or radiological progressionaccording to RECIST, version 1.1*Two or more bone meta
Last update